Canaccord analyst Edward Nash initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $106 price target The firm views Viking as a leader in the obesity drug development space. It expects a readout from the company’s two Phase 3 trials in 2027 and mid-2028, respectively. Viking also reported “strong” efficacy Phase 2 data in August from the oral version of VK2735, the analyst tells investors in a research note. Canaccord believes the drug can differentiate on “multiple fronts.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics initiated with a Buy at Canaccord
- Viking Therapeutics’ VK2735: A Promising Phase 3 Study for Weight Management
- Viking Therapeutics’ VK2735 Study: A Potential Game-Changer for Weight Management in Type 2 Diabetes
- Viking Therapeutics price target lowered to $75 from $80 at JPMorgan
- Viking Therapeutics Navigates Regulatory Risks Amid U.S. Policy Shifts